- The experience of microdosing psilocybin is characterized by a tension between subjective reports during momentary assessments and retrospective interviews, with the former revealing predominantly negative experiences while the latter often highlight positive aspects.
- Participants reported a loosening of mental structures and increased salience of stimuli in their environment, indicating that microdosing may lead to both enhanced awareness and cognitive challenges depending on the context.
- Effective harm mitigation and a better understanding of microdosing necessitate a multi-faceted approach, considering the balance between the subjective experiences reported in the moment and those recalled after the fact.
Introduction
Since the 1990s, interest in psychedelics has surged, particularly regarding their potential to treat various psychiatric conditions, including mood disorders and substance dependence. Despite strict legal regulations, the general population has widely adopted their use. Microdosing with psilocybin occurs alongside this trend but remains nuanced; individuals often pursue microdosing for enhanced performance, mood improvement, relief from symptoms, or simple curiosity.
Yet, research on psychedelics poses unique methodological challenges. Legal constraints complicate the study of these substances, especially since the subjective experiences they can engender may lead to biased research findings. While psychedelics generally exhibit an excellent safety profile in controlled environments, previous studies have warned about the risk of underestimating adverse effects. The authors aim to deepen the understanding of how microdosing fits within individuals’ broader life contexts and to identify risks that could inform harm mitigation strategies.
Methodology
Participants
The study engaged 13 participants who opted for microdosing and consented to observation. Notably, three participants stopped microdosing due to reproductive health concerns, and one encountered chronic pain issues subsequent to an infection.
Procedure
Participants provided data via the M-Path app, supplemented by phenomenological interviews that explored their lived experiences, emotions, values, and perceptions of time and space. This approach aimed to capture the essence of their experiences more holistically.
Data Analysis
The authors collected pre- and post-microdosing data, then analyzed it through grounded theory, categorizing the findings into themes around phenomenology, sensemaking, biological factors, and social dynamics.
Results
Participants exhibited mixed reactions to microdosing. They reported instances of increased creativity, mindfulness, and attentiveness to mundane events alongside a decrease in stable cognitive processes. Importantly, they noted that structured environments facilitated a more positive microdosing experience than less organized settings. Participants described a variety of emotional states, sometimes feeling overwhelmed or anxious, while others noted enhanced engagement in work.
Reflections on Methodology
The initial phase of data collection revealed altered states of consciousness that should not be strictly attributed to the microdosing itself. Specific individuals experienced intensified emotional responses that contributed to fluctuations in their well-being throughout the study. Some participants reported experiences of perceptual overstimulation, leading to feelings of anxiety, while others succeeded in utilizing their microdosing to enhance work-related productivity.
Lived Experience
Overall, participants appraised their microdosing experiences positively, even in light of certain challenging moments during data collection. Many compared the altered states induced by microdosing to other psychedelics, highlighting a spectrum of experiences ranging from mild alterations in consciousness to more pronounced effects akin to recreational use. This suggests a consistent theme where participants framed their experience in reference to mindfulness practices or prior drug interactions.
Discussion
The authors emphasized the need to differentiate between immediate perceptions during microdosing and those recalled later, noting they often yield conflicting narratives. While existing literature largely reports positive outcomes, this study highlights that a subset of participants experienced negative effects as well. This suggests that factors such as personal expectations, social settings, and prior experiences with psychedelics influence participants’ overall sensemaking.
Exploring the altered salience in every individual’s life through their own narratives reveals that classic a priori understanding of microdosing may overlook nuances relevant to participants’ psychological states. Cognitive performance results were mixed, as some participants struggled with concentration while others found a newfound engagement in their tasks. This underlines the importance of context and set and setting in the macro picture of microdosing outcomes.
Conclusion
This paper provides a preliminary exploration into the lived experiences associated with psilocybin microdosing, revealing significant discrepancies between immediate assessments and recollections over time. The authors assert the importance of employing thorough qualitative methods in future research to earnestly reflect on the psychoactive effects of microdosing, which can vary dramatically based on individual circumstances. See also our coverage of Psilocybin-assisted neurofeedback for the improvement. Read the full paper summary on Blossom.
